The content on this page is designed for Australia. Check courses designed for Canada (EN)

This course has expired. View available courses.

Oncology, Urology

Advances in therapy for patients with intermediate-to-poor risk Stage IV RCC

Immune checkpoint inhibition is the new backbone of first-line treatment in advanced clear cell RCC. This program, endorsed by the Clinical Oncology Society of Australia (COSA), focusses on the outcomes of the Checkmate 214 trial of nivolumab plus ipilimumab in untreated advanced RCC, and its recent 42 month follow-up. A useful refresher on checkpoint inhibition in cancer sets the scene, and the program also features case studies and expert videos exploring RCC prognostication, treatment selection and managing the adverse effects of checkpoint inhibitor immunotherapy.

DURATION

1 hr

PROFESSION

Specialist

# OF CREDITS

0

ACCREDITATION

Unaccredited

EXPIRY DATE

2021-04-09

Immune checkpoint inhibition is the new backbone of first-line treatment in advanced clear cell RCC. This program, endorsed by the Clinical Oncology Society of Australia (COSA), focusses on the outcomes of the Checkmate 214 trial of nivolumab plus ipilimumab in untreated advanced RCC, and its recent 42 month follow-up. A useful refresher on checkpoint inhibition in cancer sets the scene, and the program also features case studies and expert videos exploring RCC prognostication, treatment selection and managing the adverse effects of checkpoint inhibitor immunotherapy.

Faculty

Dr Laurence Krieger
Consultant Medical Oncologist and General Physicians,
St Leonards, NSW, Australia

Dr Carole Harris
Medical Oncologist,
Kogarah, NSW, Australia

Learning objectives

On completion of this program, participants will be better able to:

  • Describe the evolving treatment landscape for clear cell advanced renal cell carcinoma (RCC)
  • Evaluate the role of prognostic classification tools including IMDC and MSKCC risk classification tools
  • Describe the latest clinical data supporting the role of combination immunotherapy in the first-line treatment of patients with Stage IV intermediate-to-poor risk RCC
  • Identify patients with Stage IV RCC who may benefit from first-line combination immunotherapy
  • Feel confident in the early recognition and management of immune-related adverse events in patients treated with immunotherapy
Cost of course:  
Free
# of credits: 0
Duration: 1 hr

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.